 Connection
Brian Kavanagh to Aged, 80 and over
This is a "connection" page, showing publications Brian Kavanagh has written about Aged, 80 and over.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.924 |
|
|
|
-
Vinogradskiy Y, Jackson M, Schubert L, Jones B, Castillo R, Castillo E, Guerrero T, Mitchell J, Rusthoven C, Miften M, Kavanagh B. Assessing the use of 4DCT-ventilation in pre-operative surgical lung cancer evaluation. Med Phys. 2017 Jan; 44(1):200-208.
Score: 0.056
-
Rusthoven CG, Koshy M, Sher DJ, Ney DE, Gaspar LE, Jones BL, Karam SD, Amini A, Ormond DR, Youssef AS, Kavanagh BD. Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis. JAMA Neurol. 2016 07 01; 73(7):821-8.
Score: 0.054
-
Amini A, Jones BL, Yeh N, Rusthoven CG, Armstrong H, Kavanagh BD. Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base. Int J Radiat Oncol Biol Phys. 2015 Dec 01; 93(5):1052-63.
Score: 0.051
-
Vinogradskiy Y, Koo PJ, Castillo R, Castillo E, Guerrero T, Gaspar LE, Miften M, Kavanagh BD. Comparison of 4-dimensional computed tomography ventilation with nuclear medicine ventilation-perfusion imaging: a clinical validation study. Int J Radiat Oncol Biol Phys. 2014 May 01; 89(1):199-205.
Score: 0.047
-
Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, Robischon M, Stuhr K, Rusthoven KE, Kavanagh BD. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):1066-74.
Score: 0.036
-
McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):112-8.
Score: 0.032
-
Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 2008 Aug 15; 112(4):1175-83.
Score: 0.031
-
Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD, McCarter MD, Burri S, Nedzi LA, Sawyer TE, Gaspar LE. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006; 45(7):848-55.
Score: 0.026
-
Holt DE, Carr AL, Roberts S, Milgrom SA, Kolva E, Kavanagh BD, Switzer GE, Eitel C, Nelson J, Miller B, Shiao J, Mueller AC, Karam SD, Clapp TR. The Use of Virtual Reality for 3D Diagnostic Imaging Review Enhances Understanding and Education of Patients with Cancer. Int J Radiat Oncol Biol Phys. 2025 Aug 01; 122(5):1102-1112.
Score: 0.025
-
Poiset SJ, Lombardo J, Castillo E, Castillo R, Jones B, Miften M, Kavanagh B, Dicker AP, Boyle C, Simone NL, Movsas B, Grills I, Rusthoven CG, Vinogradskiy Y, Wilson L. Patient-Reported Outcomes: Comparing Functional Avoidance and Standard Thoracic Radiation Therapy in Lung Cancer. JCO Clin Cancer Inform. 2025 Feb; 9:e2400202.
Score: 0.025
-
Pike LRG, Miao E, Boe LA, Patil T, Imber BS, Myall NJ, Pollom EL, Hui C, Qu V, Langston J, Chiang V, Grant M, Goldberg SB, Palmer JD, Prasad RN, Wang TJC, Lee A, Shu CA, Chen LN, Thomas NJ, Braunstein SE, Kavanagh BD, Camidge DR, Rusthoven CG. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC). J Clin Oncol. 2024 Oct 20; 42(30):3606-3617.
Score: 0.024
-
Lombardo J, Castillo E, Castillo R, Miller R, Jones B, Miften M, Kavanagh B, Dicker A, Boyle C, Leiby B, Banks J, Simone NL, Movsas B, Grills I, Guerrero T, Rusthoven CG, Vinogradskiy Y. Prospective Trial of Functional Lung Avoidance Radiation Therapy for Lung Cancer: Quality of Life Report. Int J Radiat Oncol Biol Phys. 2024 Oct 01; 120(2):593-602.
Score: 0.023
-
Kavanagh BD, Fischer BA, Segreti EM, Wheelock JB, Boardman C, Roseff SD, Cardinale RM, Benedict SH, Goram AL. Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2001 Oct 01; 51(2):435-41.
Score: 0.019
-
Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK, Roberts JD, Shaw EG, Pearlman AD, Venitz J, Dusenbery KE, Abraham DJ, Gerber MJ. A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. Int J Radiat Oncol Biol Phys. 2001 Mar 15; 49(4):1133-9.
Score: 0.019
-
Vinogradskiy Y, Diot Q, Jones B, Castillo R, Castillo E, Kwak J, Bowles D, Grills I, Myziuk N, Guerrero T, Stevens C, Schefter T, Gaspar LE, Kavanagh B, Miften M, Rusthoven C. Evaluating Positron Emission Tomography-Based Functional Imaging Changes in the Heart After Chemo-Radiation for Patients With Lung Cancer. Int J Radiat Oncol Biol Phys. 2020 04 01; 106(5):1063-1070.
Score: 0.017
-
Ladbury CJ, Rusthoven CG, Camidge DR, Kavanagh BD, Nath SK. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019 10 01; 105(2):346-355.
Score: 0.017
-
Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 06 20; 37(18):1558-1565.
Score: 0.016
-
Weiss J, Kavanagh B, Deal A, Villaruz L, Stevenson J, Camidge R, Borghaei H, West J, Kirpalani P, Morris D, Lee C, Pecot CV, Zagar T, Stinchcombe T, Pennell N. Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. Cancer Treat Res Commun. 2019; 19:100126.
Score: 0.016
-
Robin TP, Breeze RE, Smith DE, Rusthoven CG, Lewis KD, Gonzalez R, Brill A, Saiki R, Stuhr K, Gaspar LE, Karam SD, Raben D, Kavanagh BD, Nath SK, Liu AK. Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases. J Neurooncol. 2018 Oct; 140(1):55-62.
Score: 0.016
-
Stokes WA, Bronsert MR, Meguid RA, Blum MG, Jones BL, Koshy M, Sher DJ, Louie AV, Palma DA, Senan S, Gaspar LE, Kavanagh BD, Rusthoven CG. Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 03 01; 36(7):642-651.
Score: 0.015
-
Stokes WA, Kavanagh BD, Raben D, Pugh TJ. Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis. Pract Radiat Oncol. 2017 Jul - Aug; 7(4):270-278.
Score: 0.015
-
Kavanagh BD, Gieschen HL, Schmidt-Ullrich RK, Arthur D, Zwicker R, Kaufman N, Goplerud DR, Segreti EM, West RJ. A pilot study of concomitant boost accelerated superfractionated radiotherapy for stage III cancer of the uterine cervix. Int J Radiat Oncol Biol Phys. 1997 Jun 01; 38(3):561-8.
Score: 0.014
-
Jackson MW, Palma DA, Camidge DR, Jones BL, Robin TP, Sher DJ, Koshy M, Kavanagh BD, Gaspar LE, Rusthoven CG. The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma. J Thorac Oncol. 2017 04; 12(4):734-744.
Score: 0.014
-
Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682.
Score: 0.014
-
Kim DN, Straka C, Cho LC, Lotan Y, Yan J, Kavanagh B, Raben D, Cooley S, Brindle J, Xie XJ, Pistenmaa D, Timmerman R. Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial. Pract Radiat Oncol. 2017 Jan - Feb; 7(1):e43-e49.
Score: 0.014
-
Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016 08 20; 34(24):2835-42.
Score: 0.014
-
Hannan R, Tumati V, Xie XJ, Cho LC, Kavanagh BD, Brindle J, Raben D, Nanda A, Cooley S, Kim DWN, Pistenmaa D, Lotan Y, Timmerman R. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Eur J Cancer. 2016 05; 59:142-151.
Score: 0.013
-
Zhao J, Yorke ED, Li L, Kavanagh BD, Li XA, Das S, Miften M, Rimner A, Campbell J, Xue J, Jackson A, Grimm J, Milano MT, Spring Kong FM. Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies. Int J Radiat Oncol Biol Phys. 2016 Aug 01; 95(5):1357-1366.
Score: 0.013
-
Amini A, Jones BL, Jackson MW, Rusthoven CG, Maroni P, Kavanagh BD, Raben D. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base. Brachytherapy. 2016 Mar-Apr; 15(2):136-46.
Score: 0.013
-
Amini A, Jones B, Jackson MW, Yeh N, Waxweiler TV, Maroni P, Kavanagh BD, Raben D. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base. J Urol. 2016 May; 195(5):1453-1458.
Score: 0.013
-
Altoos B, Amini A, Yacoub M, Bourlon MT, Kessler EE, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). Radiat Oncol. 2015 Oct 28; 10:218.
Score: 0.013
-
Brennan D, Schubert L, Diot Q, Castillo R, Castillo E, Guerrero T, Martel MK, Linderman D, Gaspar LE, Miften M, Kavanagh BD, Vinogradskiy Y. Clinical validation of 4-dimensional computed tomography ventilation with pulmonary function test data. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):423-9.
Score: 0.012
-
Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014 Dec 01; 32(34):3824-30.
Score: 0.012
-
Kim DW, Cho LC, Straka C, Christie A, Lotan Y, Pistenmaa D, Kavanagh BD, Nanda A, Kueplian P, Brindle J, Cooley S, Perkins A, Raben D, Xie XJ, Timmerman RD. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014 Jul 01; 89(3):509-17.
Score: 0.012
-
Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, Camidge DR. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):892-8.
Score: 0.011
-
Vinogradskiy Y, Diot Q, Kavanagh B, Schefter T, Gaspar L, Miften M. Spatial and dose-response analysis of fibrotic lung changes after stereotactic body radiation therapy. Med Phys. 2013 Aug; 40(8):081712.
Score: 0.011
-
Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1807-1814.
Score: 0.011
-
Howells CC, Stinauer MA, Diot Q, Westerly DC, Schefter TE, Kavanagh BD, Miften M. Normal liver tissue density dose response in patients treated with stereotactic body radiation therapy for liver metastases. Int J Radiat Oncol Biol Phys. 2012 Nov 01; 84(3):e441-6.
Score: 0.010
-
Diot Q, Kavanagh B, Schefter T, Gaspar L, Stuhr K, Miften M. Regional normal lung tissue density changes in patients treated with stereotactic body radiation therapy for lung tumors. Int J Radiat Oncol Biol Phys. 2012 Nov 15; 84(4):1024-30.
Score: 0.010
-
Kavanagh B, Anscher M, Leopold K, Deutsch M, Gaydica E, Dodge R, Allen K, Allen D, Staub W, Montana G, et al. Patterns of failure following combined modality therapy for esophageal cancer, 1984-1990. Int J Radiat Oncol Biol Phys. 1992; 24(4):633-42.
Score: 0.010
-
Amin NP, Miften M, Kavanagh B, Raben D, Camidge DR, Thornton D, Rochford N, Gaspar LE. Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer. J Thorac Oncol. 2011 Sep; 6(9):1553-62.
Score: 0.010
-
Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M, Raben D. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011 Apr 08; 6:34.
Score: 0.009
-
Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, Dinniwell R, Brierley J, Kavanagh BD, Dawson LA, Schefter TE. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011 Sep 01; 117(17):4060-9.
Score: 0.009
-
Zhang L, Kavanagh BD, Thorburn AM, Camidge DR. Preclinical and clinical estimates of the basal apoptotic rate of a cancer predict the amount of apoptosis induced by subsequent proapoptotic stimuli. Clin Cancer Res. 2010 Sep 01; 16(17):4478-89.
Score: 0.009
-
Dunlap NE, Cai J, Biedermann GB, Yang W, Benedict SH, Sheng K, Schefter TE, Kavanagh BD, Larner JM. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):796-801.
Score: 0.008
-
Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009 Apr 01; 27(10):1579-84.
Score: 0.008
-
Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009 Apr 01; 27(10):1572-8.
Score: 0.008
-
Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009 Jan 15; 69(2):609-15.
Score: 0.008
-
Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol. 2009; 48(4):578-83.
Score: 0.008
-
Olsen CC, Welsh J, Kavanagh BD, Franklin W, McCarter M, Cardenes HR, Gaspar LE, Schefter TE. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2009 Apr 01; 73(5):1414-24.
Score: 0.008
-
Arthur DW, Koo D, Zwicker RD, Tong S, Bear HD, Kaplan BJ, Kavanagh BD, Warwicke LA, Holdford D, Amir C, Archer KJ, Schmidt-Ullrich RK. Partial breast brachytherapy after lumpectomy: low-dose-rate and high-dose-rate experience. Int J Radiat Oncol Biol Phys. 2003 Jul 01; 56(3):681-9.
Score: 0.005
-
Manning MA, Wu Q, Cardinale RM, Mohan R, Lauve AD, Kavanagh BD, Morris MM, Schmidt-Ullrich RK. The effect of setup uncertainty on normal tissue sparing with IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001 Dec 01; 51(5):1400-9.
Score: 0.005
-
Manning MA, Cardinale RM, Benedict SH, Kavanagh BD, Zwicker RD, Amir C, Broaddus WC. Hypofractionated stereotactic radiotherapy as an alternative to radiosurgery for the treatment of patients with brain metastases. Int J Radiat Oncol Biol Phys. 2000 Jun 01; 47(3):603-8.
Score: 0.004
-
Lutz ST, Huang DT, Ferguson CL, Kavanagh BD, Tercilla OF, Lu J. A retrospective quality of life analysis using the Lung Cancer Symptom Scale in patients treated with palliative radiotherapy for advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 1997 Jan 01; 37(1):117-22.
Score: 0.004
-
Arthur D, Kaufman N, Schmidt-Ullrich R, Kavanagh B, Simpson P, Hill M, Ali M. Heuristically derived tumor burden score as a prognostic factor for stage IIIB carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 1995 Feb 15; 31(4):743-51.
Score: 0.003
-
Mak AC, Rich TA, Schultheiss TE, Kavanagh B, Ota DM, Romsdahl MM. Late complications of postoperative radiation therapy for cancer of the rectum and rectosigmoid. Int J Radiat Oncol Biol Phys. 1994 Feb 01; 28(3):597-603.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|